Overall, the development of irAEs is associated with improved ICI efficacy and OS [14,15], yet severe CIP decreased PFS and OS in NSCLC patients treated with anti-PD(L)1 therapy [16]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.